CMS In Brief
This article was originally published in The Gray Sheet
Executive Summary
MedCAC posts meeting questions: CMS has 1posted a list of voting questions for the Medicare Evidence Development and Coverage Advisory Committee to address during its Sept. 22 meeting on evidence for on- and off-label use of bone morphogenetic proteins. CMS wants feedback on MedCAC's level of confidence that FDA-approved uses of BMPs can improve outcomes related to the lumbar spine, open tibia fractures and recalcitrant long bone nonunion and that off-label use can improve outcomes in the cervical spine, the lumbar spine or elsewhere. The panel will review evidence on BMP products from Medtronic and Stryker. On July 27, an FDA advisory panel had a mixed response to Medtronic's Amplify rhBMP-2 Matrix spinal treatment, currently under PMA review for posterolateral spine fusion